Affirmed Therapeutics BV (NASDAQ:AFMD) was down 5.7% during mid-day trading on Monday . The stock traded as low as $2.65 and last traded at $2.65, with a volume of 79,327 shares trading hands. The stock had previously closed at $2.81.

AFMD has been the subject of several recent research reports. Leerink Swann initiated coverage on Affirmed Therapeutics BV in a report on Saturday, April 2nd. They issued a “buy” rating for the company. Wells Fargo & Co. reissued a “buy” rating on shares of Affirmed Therapeutics BV in a report on Wednesday, May 18th. Jefferies Group decreased their price objective on Affirmed Therapeutics BV from $5.00 to $4.00 and set a “hold” rating for the company in a report on Thursday, May 19th. Finally, BMO Capital Markets initiated coverage on Affirmed Therapeutics BV in a report on Monday, April 11th. They issued an “outperform” rating and a $7.00 price objective for the company. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $9.46.

The firm’s 50-day moving average price is $2.95 and its 200-day moving average price is $3.54. The company’s market capitalization is $89.69 million.

Affirmed Therapeutics BV (NASDAQ:AFMD) last posted its earnings results on Wednesday, May 18th. The biopharmaceutical company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.17) by $0.08. The company earned $1.90 million during the quarter, compared to analysts’ expectations of $1.88 million. The business’s revenue for the quarter was down 24.0% on a year-over-year basis. On average, equities research analysts expect that Affirmed Therapeutics BV will post ($1.04) earnings per share for the current fiscal year.

A hedge fund recently raised its stake in Affirmed Therapeutics BV stock. Tekla Capital Management LLC raised its stake in shares of Affirmed Therapeutics BV (NASDAQ:AFMD) by 29.0% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 294,213 shares of the biopharmaceutical company’s stock after buying an additional 66,130 shares during the period. Tekla Capital Management LLC owned approximately 0.97% of Affirmed Therapeutics BV worth $2,095,000 as of its most recent SEC filing.

Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company’s product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body’s own immune system to fight tumor cells.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.